Targeting MDM2 and MDMX in retinoblastoma

Nikia A. Laurie, Chie-Schin Shih, Michael A. Dyer

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Retinoblastoma is the third most common form of cancer in infants, and metastatic retinoblastoma is lethal in approximately 90% of cases. Early detection and aggressive therapy has resulted in a 95% probability of survival for retinoblastoma patients in the United States. However, the United States only represents 3-4% of the retinoblastoma cases worldwide. The majority of children diagnosed with retinoblastoma each year live in developing countries where the probability of survival is closer to 50%. This difference in survival rates reflects poor early detection rates and limited resources for the aggressive therapy necessary to treat retinoblastoma and manage the side effects associated with broad-spectrum systemic chemotherapy in young children. In order to have the most significant impact on retinoblastoma treatment in the United States and worldwide, current efforts have focused on local delivery of targeted chemotherapy. In this review, we summarize recent data showing that the p53 pathway is inactivated in 75% of retinoblastoma patients due to extra copies of the MDM2 and MDMX genes. A small molecule inhibitor of MDM2 called nutlin-3 can induce p53-mediated cell death in retinoblastoma cells. Subconjunctival delivery of nutlin-3 in preclinical models of retinoblastoma confirmed the efficacy of this approach in vivo. The advantage of local application of targeted chemotherapeutic agents such as nutlin-3 is that greater intraocular drug concentrations can be achieved without the side effects associated with systemic broad-spectrum chemotherapy. We propose that subconjunctival administration of targeted chemotherapy may be the best treatment option for children with retinoblastoma in the United States and throughout the developing world because it provides greater tumor response without the costs and complications associated with current treatment protocols.

Original languageEnglish (US)
Pages (from-to)689-695
Number of pages7
JournalCurrent Cancer Drug Targets
Volume7
Issue number7
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Retinoblastoma
Drug Therapy
Survival
Therapeutics
Clinical Protocols
Developing Countries
Neoplasms
Cell Death
Survival Rate
Costs and Cost Analysis

Keywords

  • MDM2
  • MDMX
  • Nutlin-3
  • p53
  • Topotecan

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Cancer Research

Cite this

Targeting MDM2 and MDMX in retinoblastoma. / Laurie, Nikia A.; Shih, Chie-Schin; Dyer, Michael A.

In: Current Cancer Drug Targets, Vol. 7, No. 7, 11.2007, p. 689-695.

Research output: Contribution to journalArticle

Laurie, Nikia A. ; Shih, Chie-Schin ; Dyer, Michael A. / Targeting MDM2 and MDMX in retinoblastoma. In: Current Cancer Drug Targets. 2007 ; Vol. 7, No. 7. pp. 689-695.
@article{b7fd71808b9740fcb6781ded293c5d9b,
title = "Targeting MDM2 and MDMX in retinoblastoma",
abstract = "Retinoblastoma is the third most common form of cancer in infants, and metastatic retinoblastoma is lethal in approximately 90{\%} of cases. Early detection and aggressive therapy has resulted in a 95{\%} probability of survival for retinoblastoma patients in the United States. However, the United States only represents 3-4{\%} of the retinoblastoma cases worldwide. The majority of children diagnosed with retinoblastoma each year live in developing countries where the probability of survival is closer to 50{\%}. This difference in survival rates reflects poor early detection rates and limited resources for the aggressive therapy necessary to treat retinoblastoma and manage the side effects associated with broad-spectrum systemic chemotherapy in young children. In order to have the most significant impact on retinoblastoma treatment in the United States and worldwide, current efforts have focused on local delivery of targeted chemotherapy. In this review, we summarize recent data showing that the p53 pathway is inactivated in 75{\%} of retinoblastoma patients due to extra copies of the MDM2 and MDMX genes. A small molecule inhibitor of MDM2 called nutlin-3 can induce p53-mediated cell death in retinoblastoma cells. Subconjunctival delivery of nutlin-3 in preclinical models of retinoblastoma confirmed the efficacy of this approach in vivo. The advantage of local application of targeted chemotherapeutic agents such as nutlin-3 is that greater intraocular drug concentrations can be achieved without the side effects associated with systemic broad-spectrum chemotherapy. We propose that subconjunctival administration of targeted chemotherapy may be the best treatment option for children with retinoblastoma in the United States and throughout the developing world because it provides greater tumor response without the costs and complications associated with current treatment protocols.",
keywords = "MDM2, MDMX, Nutlin-3, p53, Topotecan",
author = "Laurie, {Nikia A.} and Chie-Schin Shih and Dyer, {Michael A.}",
year = "2007",
month = "11",
doi = "10.2174/156800907782418266",
language = "English (US)",
volume = "7",
pages = "689--695",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Targeting MDM2 and MDMX in retinoblastoma

AU - Laurie, Nikia A.

AU - Shih, Chie-Schin

AU - Dyer, Michael A.

PY - 2007/11

Y1 - 2007/11

N2 - Retinoblastoma is the third most common form of cancer in infants, and metastatic retinoblastoma is lethal in approximately 90% of cases. Early detection and aggressive therapy has resulted in a 95% probability of survival for retinoblastoma patients in the United States. However, the United States only represents 3-4% of the retinoblastoma cases worldwide. The majority of children diagnosed with retinoblastoma each year live in developing countries where the probability of survival is closer to 50%. This difference in survival rates reflects poor early detection rates and limited resources for the aggressive therapy necessary to treat retinoblastoma and manage the side effects associated with broad-spectrum systemic chemotherapy in young children. In order to have the most significant impact on retinoblastoma treatment in the United States and worldwide, current efforts have focused on local delivery of targeted chemotherapy. In this review, we summarize recent data showing that the p53 pathway is inactivated in 75% of retinoblastoma patients due to extra copies of the MDM2 and MDMX genes. A small molecule inhibitor of MDM2 called nutlin-3 can induce p53-mediated cell death in retinoblastoma cells. Subconjunctival delivery of nutlin-3 in preclinical models of retinoblastoma confirmed the efficacy of this approach in vivo. The advantage of local application of targeted chemotherapeutic agents such as nutlin-3 is that greater intraocular drug concentrations can be achieved without the side effects associated with systemic broad-spectrum chemotherapy. We propose that subconjunctival administration of targeted chemotherapy may be the best treatment option for children with retinoblastoma in the United States and throughout the developing world because it provides greater tumor response without the costs and complications associated with current treatment protocols.

AB - Retinoblastoma is the third most common form of cancer in infants, and metastatic retinoblastoma is lethal in approximately 90% of cases. Early detection and aggressive therapy has resulted in a 95% probability of survival for retinoblastoma patients in the United States. However, the United States only represents 3-4% of the retinoblastoma cases worldwide. The majority of children diagnosed with retinoblastoma each year live in developing countries where the probability of survival is closer to 50%. This difference in survival rates reflects poor early detection rates and limited resources for the aggressive therapy necessary to treat retinoblastoma and manage the side effects associated with broad-spectrum systemic chemotherapy in young children. In order to have the most significant impact on retinoblastoma treatment in the United States and worldwide, current efforts have focused on local delivery of targeted chemotherapy. In this review, we summarize recent data showing that the p53 pathway is inactivated in 75% of retinoblastoma patients due to extra copies of the MDM2 and MDMX genes. A small molecule inhibitor of MDM2 called nutlin-3 can induce p53-mediated cell death in retinoblastoma cells. Subconjunctival delivery of nutlin-3 in preclinical models of retinoblastoma confirmed the efficacy of this approach in vivo. The advantage of local application of targeted chemotherapeutic agents such as nutlin-3 is that greater intraocular drug concentrations can be achieved without the side effects associated with systemic broad-spectrum chemotherapy. We propose that subconjunctival administration of targeted chemotherapy may be the best treatment option for children with retinoblastoma in the United States and throughout the developing world because it provides greater tumor response without the costs and complications associated with current treatment protocols.

KW - MDM2

KW - MDMX

KW - Nutlin-3

KW - p53

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=35948990075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948990075&partnerID=8YFLogxK

U2 - 10.2174/156800907782418266

DO - 10.2174/156800907782418266

M3 - Article

VL - 7

SP - 689

EP - 695

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 7

ER -